Sacral root neuromodulation. Experience in our site: 1998-2003, concerning 18 definite neuromodulation implants

• Published in: Actas urologicas españolas Vol. 28; no. 10; pp. 732 - 742
• Main Authors: Gómez García, I, Fernández Fernández, E, Sanz Mayayo, E, Conde Someso, S, García Navas, R, Quicios Dorado, C, Linares Quevedo, A, Perales Cabanas, L, Jiménez Cidre, M, Escudero Barrilero, A
• Format: Journal Article
• Language: Spanish
• Published: Spain 01-11-2004
• Subjects: Adult; Aged; Chronic Disease; Electric Stimulation Therapy - methods; Female; Humans; Lumbosacral Plexus; Male; Middle Aged; Prostheses and Implants; Urination Disorders - therapy
• ISSN: 0210-4806

Sacral root neuromodulation is an effective technique for the treatment of Chronic Micturition Dysfunction (CMD) refractory to conventional therapy. New indications such as chronic pelvic pain and interstitial cystitis are currently making their way within the urologic setting. Several groups of gastric surgeons are now choosing this technique for the management of rectal diseases (constipation, sphincter dysfunction). This paper contributes our experience in the treatment of patients with CMD and the comparative results at one year from implant in all patients.
From December 1998 through July 2003, 18 neuromodulation definite implants were performed. The main indication was CMD in 62.5% patients. Follow up of patients was done at one month and three months, and every six months thereafter. Follow up is conducted through a micturition diary and QoL questionnaire. Electrode implant in the first 16 patients was achieved by open surgery. The next 2 patients had the electrode placed by a percutaneous technique using the "Tined Lead" kit.
Results at one year after implant were compared in all patients. The total number of neuromodulation implants placed was 18, 14 (77.7%) of which were women and 4 (22.3%) men. Mean age was 52.56 years. Implant indication was CMD in 72.2% patients, mixed incontinence (urinary and faecal) in 22.1%, and interstitial cystic disease in 5.5%. Symptoms improvement at one year from implant, as determined by a micturition diary and QoL questionnaire was 76.4%. Clinical improvement was greater in patients with urgency symptoms than in patients with predominance of voiding symptoms.